4552.T
JCR Pharmaceuticals Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 527.00
+0.76%Jun 17, 2026, 16:30 UTC
Acumen Pharmaceuticals exercised its exclusive option to develop therapeutic candidates for Alzheimer's disease using JCR Pharmaceuticals' J-Brain Cargo technology platform.
Jun 16, 2026, 11:30 UTC
Acumen Pharmaceuticals nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery program for Alzheimer's disease treatment.
Source: